These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 25327734)

  • 1. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

  • 3. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
    [No Abstract]   [Full Text] [Related]  

  • 4. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
    Tang XH; Li M; Deng S; Lu MS
    Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.
    Tang XH; Li H; Zheng XS; Lu MS; An Y; Zhang XL
    Cancer Med; 2019 Oct; 8(14):6426-6436. PubMed ID: 31490008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
    Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
    Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
    Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
    Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
    Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
    Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
    Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells].
    Li ZM; Hu S; Xiao L; Wang J; Cai J; Yu LL; Wang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):372-5. PubMed ID: 20646448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
    Dateoka S; Ohnishi Y; Kakudo K
    Med Mol Morphol; 2012 Jun; 45(2):91-7. PubMed ID: 22718294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
    Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
    Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel].
    Xiao L; Gao R; Lu S; Lu MS; Liang ML; Ren LR; Wang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):412-6. PubMed ID: 17697605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
    Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
    Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of estrogen or progesterone combined with paclitaxel on human ovarian cancer cell growth and Drosha expression].
    Yang Y; Han K; Xie Y
    Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):578-84. PubMed ID: 26714597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of cyclin-dependent kinase inhibitor p27 on resistance of ovarian cancer multicellular spheroids to taxol].
    Xing H; Li J; Gao QL; Wu JH; Gao C; Lu YP; Ma D
    Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(1):37-41. PubMed ID: 12757643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide reverses the resistance of A2780/Pacliaxel ovarian cancer cell line to paclitaxel chemotherapy in vitro.
    Shen Y; Zhang XY; Chen X; Ren ML; Cai YL
    J Cancer Res Ther; 2016; 12(2):657-62. PubMed ID: 27461627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
    Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P
    Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.